News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Pathway For Malaria Infection Discovered by Cenix BioScience GmbH, Alnylam Pharmaceuticals (ALNY) and Instituto de Medicina Molecular Researchers


9/15/2008 7:50:40 AM

ScienceDaily (Sep. 15, 2008) — Cenix BioScience GmbH, a leading specialist in advanced RNA interference (RNAi)-based research services, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and the Lisbon-based biomedical research centre Instituto de Medicina Molecular (IMM), have announced the publication of their collaborative study in Cell Host & Microbe, describing the discovery and in vivo validation of scavenger receptor BI (SR-BI), a major regulator of cholesterol uptake by the liver, as a critical host factor for malaria infection.

Read at ScienceDaily

comments powered by Disqus
   
Malaria

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES